- PA1-748 - Invitrogen Antibodies TRPV1 antibody

Submitted references Convergence of peptidergic and non-peptidergic protein markers in the human dorsal root ganglion and spinal dorsal horn.

Shiers SI, Sankaranarayanan I, Jeevakumar V, Cervantes A, Reese JC, Price TJ
The Journal of comparative neurology 2021 Jul 1;529(10):2771-2788

Inhibition of carrageenan-induced dental inflammatory responses owing to decreased TRPV1 activity by Dexmedetomidine.

Lv G, Zhu G, Xu M, Gao X, Xiao Q
Journal of inflammation (London, England) 2020;17:18

Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer.

Han GH, Chay DB, Nam S, Cho H, Chung JY, Kim JH
Cancer genomics & proteomics 2020 May-Jun;17(3):309-319

Inhibitory Effect of Sirtuin6 (SIRT6) on Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells.

Xiao F, Zhou Y, Liu Y, Xie M, Guo G
Medical science monitor : international medical journal of experimental and clinical research 2019 Nov 8;25:8412-8421

Sirtuin6 inhibits c-triggered inflammation through TLR4 abrogation regulated by ROS and TRPV1/CGRP.

Zhang R, Li H, Guo Q, Zhang L, Zhu J, Ji J
Journal of cellular biochemistry 2018 Nov;119(11):9141-9153

Activation of endogenous TRPV1 fails to induce overstimulation-based cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons.

Pecze L, Jósvay K, Blum W, Petrovics G, Vizler C, Oláh Z, Schwaller B
Biochimica et biophysica acta 2016 Aug;1863(8):2054-64

Vanilloids induce oral cancer apoptosis independent of TRPV1.

Gonzales CB, Kirma NB, De La Chapa JJ, Chen R, Henry MA, Luo S, Hargreaves KM
Oral oncology 2014 May;50(5):437-47

The neurochemical changes in the innervation of human colonic mesenteric and submucosal blood vessels in ulcerative colitis and Crohn's disease.

de Fontgalland D, Brookes SJ, Gibbins I, Sia TC, Wattchow DA
Neurogastroenterology and motility 2014 May;26(5):731-44

TRPV1 and TRPA1 stimulation induces MUC5B secretion in the human nasal airway in vivo.

Alenmyr L, Herrmann A, Högestätt ED, Greiff L, Zygmunt PM
Clinical physiology and functional imaging 2011 Nov;31(6):435-44

Transient receptor potential vanilloid 1, vanilloid 2 and melastatin 8 immunoreactive nerve fibers in human skin from individuals with and without Norrbottnian congenital insensitivity to pain.

Axelsson HE, Minde JK, Sonesson A, Toolanen G, Högestätt ED, Zygmunt PM
Neuroscience 2009 Sep 15;162(4):1322-32

Human keratinocytes are vanilloid resistant.

Pecze L, Szabó K, Széll M, Jósvay K, Kaszás K, Kúsz E, Letoha T, Prorok J, Koncz I, Tóth A, Kemény L, Vizler C, Oláh Z
PloS one 2008;3(10):e3419

The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate.

Dinis P, Charrua A, Avelino A, Nagy I, Quintas J, Ribau U, Cruz F
European urology 2005 Jul;48(1):162-7

Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.

Karai L, Brown DC, Mannes AJ, Connelly ST, Brown J, Gandal M, Wellisch OM, Neubert JK, Olah Z, Iadarola MJ
The Journal of clinical investigation 2004 May;113(9):1344-52

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Frozen human skin tissue sections were fixed with paraformaldehyde and stained with PA1-748 (1:250) followed by a biotin-conjugated donkey anti-rabbit IgG secondary antibody and streptavidin-HRP/tyrimide-fluorescent detection system. Vanilloid Receptor 1 staining is shown in red. Data courtesy of the Innovators Program.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunolocalization of VR1 in human glabrous skin using Product # PA1-748.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Transformed cells expressing low levels of TRPV1 were resistant to TRPV1-mediated capsaicin toxicity. NIH3T3 mouse fibroblasts expressing variable levels of TRPV1-YFP fusion protein were incubated in the absence of capsaicin (A) or with different capsaicin concentrations, 0.1 uM (B), 1 uM (C), 10 uM (D) for 30', then propidium iodide was added and the flow-cytofluorometric analysis was performed. The M1 and M2 regions contain the intact (propidium iodide negative) TRPV1-YFP high and low positive cells, respectively. Only TRPV1 high positive cells were sensitive to dose dependent, TRPV1 mediated killing by capsaicin (E).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 The TRPV1 protein level in the keratinocytes was under detection limit in Western blotting assay. Proteins were extracted from human trigeminal ganglion (TG), primary human keratinocytes (NEHK) and the HaCaT cell lines. With a commercially available polyclonal antibody only the TG expressed 94 kDa TRPV1 can be detected (A). The equal loading of protein extracts was validated by beta-actin (~50 kDa), a common, ubiquitously expressed cytoskeletal protein (B).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 Dex desensitized the TRPV1 channel in hDPCs. a qPCR revealed the expression of TRPV1 in hDPCs. b The release of CGRP in cell culture medium was determined at 2 h after Car and/or Dex cotreatment by ELISA. c WB analyses determined the expression and phosphorylation of TRPV1 in hDPCs. Data are expressed as means +- standard deviations. Comparisons between two groups were analyzed by t -test. ** P < 0.01

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Cap treatment restored Car-induced inflammation in hDPCs. hDPCs were cotreated with Car (100 muM), Dex (5 muM), and/or Cap (5 muM) for 2 h. a The release of CGRP in cell culture medium was determined at 2 h after Car and/or Dex cotreatment by ELISA. b WB analyses were used to examine the phosphorylation and expression of PKA, PKC, STAT3, NF-kappaB, and TRPV1 in cell lysates. c ELISA was conducted to assess IL-1beta, IL-6, and TNF-alpha expression. Data are expressed as means +- standard deviations. Comparisons between two groups were analyzed by t -test. ** P < 0.01, *** P < 0.001

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 5 FIGURE Immunohistochemistry for TrpV1 in human lumbar dorsal root ganglion. (a) Representative 10X images showing TrpV1 (red), peripherin (a sensory neuron marker; green) and DAPI (blue) in human dorsal root ganglion (DRG). The negative control was exposed only to secondary antibody and was imaged at the same settings. (b) TrpV1 was expressed in 57.8% of all human sensory neurons. The total number of neurons assessed between all three donors is shown on the bar graph. (c) Histogram with Gaussian distribution displaying the size profile of all TrpV1 - positive neurons. DRGs from donors 1, 4, and 5 were used for this experiment. Scale bar = 100 mum [Color figure can be viewed at wileyonlinelibrary.com ]

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 11 FIGURE Immunohistochemistry for TrpV1 and Nav1.7 in human lumbar spinal cord. Representative 10X images showing TrpV1 (red), Nav1.7 (green), Peripherin (blue), and DAPI (cyan) staining in human spinal cord. The negative control was exposed only to secondary antibody and was imaged at the same settings. Spinal cords from donors 1, 2, 3, and 4 were used for this experiment. TrpV1 and Nav1.7 neuropil staining could be seen throughout the spinal dorsal horn. TrpV1 also robustly labeled glial cells. Scale bar = 100 mum [Color figure can be viewed at wileyonlinelibrary.com ]

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Downregulation of TRPV1 by SIRT6 overexpression. The hMSCs were transfected with SIRT6-expressing vector, and OD was induced. ( A ) Western blot analysis results showing TRPV1 expression during SIRT6 overexpression. ( B ) Western blot analysis results revealed the ubiquitination level of TRPV1 under SIRT6 overexpression. ( C ) ELISA was utilized to detect released CGRP. N=3. One-way ANOVA was used for comparative analyses of the data in ( C ). * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Evaluation of the effect of capsaicin on SIRT6-mediated OD. The hMSCs were transfected with SIRT6 overexpression vector, and treated with 10 muM capsaicin for 12 h. ( A ) ELISA was utilized to detect released CGRP. ( B ) Western blot analysis was performed to detect SIRT6 and TRPV1 protein levels. ( C ) Levels of the osteoblastic markers OPN , OCN , BSP , RUNX2 , and ALP were determined via qPCR for each group on day 14 after induction. ( D ) The activity of ALP was detected in each group in OD. ( E ) AR staining was performed to detect matrix mineralization of hMSCs between different treatments on day 14 following induction. N=3. One-way ANOVA was used for comparative analyses of the data in ( A, C, D ). * P

PA1-748

Antibody data